Global Health Investment Fund

The Global Health Investment Fund (GHIF) is a social impact investment fund established in 2012 with a focus on empowering global health through targeted investments in life-saving solutions for resource-limited communities. With a slogan of "Empowering global health through targeted investments in life-saving solutions for resource-limited communities," GHIF has a fund size of $108 million, and it targets late-stage innovations addressing public health challenges in low- and middle-income countries. This includes diseases like malaria, pre-eclampsia, cholera, HIV, and river blindness, particularly in resource-constrained settings. GHIF's investment approach targets opportunities with a high likelihood of successful commercialization within two to three years, with a keen interest in products that have a dual market potential - benefiting public health in developing countries while also holding value in high-income countries. The fund focuses on supporting projects that enhance or expand access to existing products, such as pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines. The fund uses various investment structures, including mezzanine debt, convertible debt, preferred equity, and project financing, with an average investment target around $10 million per project. As an impact-driven fund, each project must align with GHIF’s social impact objectives and demonstrate potential for commercial success. GHIF operates in the Biotechnology, Financial Services, and Health Care industries, with its headquarters located in the United States. As of now, specific details about the last investment and the last investment investors are not available.